Want to see INIS full AI Analyst Report?
Top Page
International Isotopes
(OTC:INIS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.07
▲(11.67% Upside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (declining revenue, persistent operating losses, large net losses, and elevated leverage). Technicals are weak-to-neutral with price below key moving averages and a negative MACD. Corporate events are mixed but lean risk-positive/negative overall due to the terminated asset sale and recall, while valuation inputs (P/E and dividend yield) do not provide clear support.
Positive Factors
High gross margin
A TTM gross margin near 69% implies durable product-level profitability from specialized radioisotope manufacturing. High gross margins provide a structural cushion to absorb SG&A and R&D, supporting the path to operating leverage if revenue stabilizes or grows and fixed costs are managed.
Negative Factors
Declining revenue trend
A near-25% TTM revenue decline signals durable top-line weakness or customer loss. Sustained revenue contraction reduces scale, strains absorption of fixed costs, undermines leverage of high gross margins, and makes profitable recovery harder without clear demand- or contract-driven growth initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margin
A TTM gross margin near 69% implies durable product-level profitability from specialized radioisotope manufacturing. High gross margins provide a structural cushion to absorb SG&A and R&D, supporting the path to operating leverage if revenue stabilizes or grows and fixed costs are managed.
Read all positive factors
International Isotopes (INIS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.05M
Dividend YieldN/A
Average Volume (3M)97.60K
Price to Earnings (P/E)―
Beta (1Y)0.92
Revenue Growth-14.22%
EPS Growth-4200.00%
CountryUS
Employees41
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-1723.63
Shares Outstanding529,130,400
10 Day Avg. Volume65,048
30 Day Avg. Volume97,599
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)8.74
Price to Sales (P/S)2.47
P/FCF Ratio375.15
Enterprise Value/Market Cap1.17
Enterprise Value/Revenue3.64
Enterprise Value/Gross Profit8.05
Enterprise Value/Ebitda-31.51
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
International Isotopes Business Overview & Revenue Model
Company Description
Radnostix, Inc. (INIS) is a company that specializes in the global manufacturing and sale of crucial nuclear medicine calibration and reference standards, cobalt-60 products, and offers contract services for producing radiopharmaceuticals and radi...
How the Company Makes Money
INIS makes money primarily by selling radioisotope-based products and related services. Key revenue streams typically include: (1) sales of medical radioisotopes and/or isotope-derived materials used by nuclear pharmacies, hospitals, and imaging c...
International Isotopes Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
34
Negative
| Breakdown | Mar 2026 | Dec 2024 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 13.07M | 13.90M | 12.27M | 11.18M | 9.66M |
| Gross Profit | 3.21M | 8.65M | 7.38M | 6.29M | 5.74M |
| EBITDA | -166.28K | 804.17K | -163.13K | 1.31M | 631.12K |
| Net Income | -908.00K | 8.57K | -869.02K | -310.70K | -2.38M |
Balance Sheet | |||||
| Total Assets | 17.84M | 17.16M | 16.91M | 16.24M | 16.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.70T | 1.95M | 2.69M | 2.38M | 474.85K |
| Total Debt | 4.84T | 8.36M | 8.34M | 4.05M | 4.46M |
| Total Liabilities | 14.14M | 12.81M | 12.87M | 11.90M | 13.60M |
| Stockholders Equity | 3.69M | 4.35M | 4.04M | 4.34M | 2.73M |
Cash Flow | |||||
| Free Cash Flow | 86.01K | -82.43K | 433.53K | -1.62M | -367.39K |
| Operating Cash Flow | 620.16K | 638.78K | 582.59K | -1.50M | -161.91K |
| Investing Cash Flow | -534.15K | -685.22K | -149.06K | 3.88M | -205.47K |
| Financing Cash Flow | -275.86K | -145.23K | -80.50K | -472.00K | -78.70K |
International Isotopes Technical Analysis
Negative
0.06
Price Trends
0.08
Negative
0.08
Negative
0.07
Negative
Market Momentum
>-0.01
Negative
45.43
Neutral
33.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INIS, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.08, and below the 200-day MA of 0.07, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 33.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INIS.
International Isotopes Risk Analysis
International Isotopes disclosed 23 risk factors in its most recent earnings report. International Isotopes reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
International Isotopes Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $53.46M | -2.87 | -92.98% | ― | -96.30% | 32.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $25.70M | -4.39 | -15.41% | ― | -30.75% | -1056.69% | |
47 Neutral | $23.29M | -0.51 | -107.16% | ― | -18.24% | -2264.65% | |
44 Neutral | $38.23M | -1.08 | -57.16% | ― | 673.54% | 23.14% | |
41 Neutral | $38.05M | ― | -5.69% | ― | -14.22% | -4200.00% | |
40 Underperform | $949.33K | -0.07 | -157.67% | ― | ― | ― |
* Healthcare Sector Average
INIS
International Isotopes
0.07
>-0.01
-11.25%
TLPH
Talphera
1.03
0.57
123.91%
PRPH
Prophase Labs
0.10
-3.81
-97.44%
RMTI
Rockwell Med
0.65
-0.20
-23.23%
SCYX
SCYNEXIS
3.85
-1.55
-28.68%
AYTU
Aytu BioScience
2.17
-0.01
-0.46%
International Isotopes Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Radnostix Extends Series C Preferred Stock Maturity Date
Positive
May 20, 2026
On May 14, 2026, Radnostix, Inc. obtained approval from a majority of holders of its Series C Convertible Redeemable Preferred Stock to modify the security’s terms by extending its maturity date by one year to Feb. 28, 2028, while leaving al...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
International Isotopes Regains DUF6 Plant After Deal Termination
Negative
Mar 16, 2026
On February 19, 2026, Radnostix discovered in an internal audit that certain lots of dibasic sodium phosphate capsules bundled with its generic sodium iodide I-131 kits manufactured between 2022 and 2025 were out of specification on final capsule ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.